Q4 2021 Results
Company overview
Pharmaceuticals
Participants
Financial performance
Oncology
Financial review
Conclusion
Innovation: Pipeline overview
Novartis pipeline in registration
Oncology
Code
Name
AAA617
177Lu-PSMA-617
BYL719 alpelisib
CTL019 KymriahⓇ
INC424 Jakavi®
Mechanism
Radioligand therapy
target PSMA
PI3Ka inhibitor
CD19 CAR-T
JAK1/2 inhibitor
VDT482 tislelizumab
PD1 inhibitor
Indication(s)
Metastatic castration-resistant prostate cancer, post-taxane
PIK3CA-related overgrowth spectrum
r/r Follicular lymphoma
Acute GVHD
Chronic GVHD
2L ESCC
Immunology
Code
Name
AIN457 CosentyxⓇ
Ophthalmology
Mechanism
IL17A inhibitor
Indication(s)
Cosentyx 300mg auto-injector and pre-filled syringe
Code
Name
RTH258 BeovuⓇ
Mechanism
Indication(s)
VEGF inhibitor
Diabetic macular edema
63 Investor Relations | Q4 2021 Results
Appendix
Innovation: Clinical trials
2 lead indication
Lead indication
NOVARTIS | Reimagining MedicineView entire presentation